91̽»¨

Research summary

Our research seek to identify biomarkers of response to new targeted therapies and immunotherapies. We are making personalized animal models, so called PDX models or Avatar mice. These are used to test drugs as well as further humanization for use in immune oncology research.

The group has initiated and/or participated in several clinical trials, eg the SCANDIUM 1/2 trials, PEMDAC, HAITILS and MEGALIT. Patient samples from the trial has generated important knowledge about genetics and immunology of cancer and immunotherapy.

Focus currently is on cell and RNA therapy combined with tumor targeting drugs. Large national and international collaborations drive development of new generations of treatment for therapy resistant cancers like melanoma and pancreatic cancer.

Group members at SCCR

Group leader:
Jonas Nilsson, PhD, Group leader at Sahlgrenska Center for Cancer Research and Professor of Experimental Cancer Surgery

Preclinic/translational researchers:
Lisa Nilsson, PhD, Senior staff scientist
Maria Öberg, PhD, Postdoctoral fellow
Carina Karlsson, Biomedical Scientist
Sofia Stenqvist, Animal Research Assistant

Kliniska samt GMP-forskare:
Lars Ny, MD/PhD, Professor, onkology
Axel Nelson, MD/PhD, Postdoctoral fellow
Rebecca Riise, PhD, Researcher
David Jansson, Resident, PhD student 

Selected publications

1. 
   Karlsson JW, Sah VR, Olofsson Bagge R, Kuznetsova I, Iqba M, Alsen S, Stenqvist S, Saxena A, Ny L, Nilsson LM, Nilsson JA. Elife. 2024 Sep 23;12:RP91705. doi: 10.7554/eLife.91705.
    
2. 
   Ny L, Jespersen H, Karlsson J, Alsén S, Filges S, All-Eriksson C, Andersson B, Carneiro A, Helgadottir H, Levin M, Ljuslinder I, Olofsson Bagge R, Sah V, Stierner U, StÃ¥hlberg A, Ullenhag G, Nilsson LM, Nilsson JA. Nature communications, 2021, epub.
    
3. 
   Karlsson J, Nilsson LM, Mitra S, Alsén S, Shelke GS, Sah VR, Forsberg EMV, Stierner U, All-Eriksson C, Einarsdottir BO, Jespersen H, Ny L, Lindnér P, Larsson E, Olofsson Bagge R, Nilsson JA. Nature communications, 2020, 11:1894
    
4. 
   Ny L, Rizzo LY, Belgrano V, Karlsson J, Jespersen J, Carstam L, Olofsson Bagge R, Nilsson LM, Nilsson JA. Annals of Oncology, 2020, 31:266-273
    
5. 
   Hofving T, Karlsson J, Nilsson, O, Nilsson JA. Nature Genetics, 2019, 51:1426-1427
    
6. 
   Forsberg EM, Lindberg MF, Jespersen H, Alsén S, Olofsson Bagge R, Donia M, Svane IM, Nilsson O, Ny L, Nilsson LM, Nilsson JA. Cancer Res. 2019
    
7. 
   Jespersen H, Lindberg MF, Donia M, Söderberg EMV, Andersen R, Keller U, Ny L, Svane IM, Nilsson LM, Nilsson JA. Nature communications. 2017; 8(1):707. 
    
8. 
   Bhadury J, Nilsson LM, Muralidharan SV, Green LC, Li Z, Gesner EM, Hansen HC, Keller UB, McLure KG, Nilsson JA. Proceedings of the National Academy of 91̽»¨s of the United States of America. 2014; 111(26):E2721-30.
    
9. 
   Höglund A, Nilsson LM, Muralidharan SV, Hasvold LA, Merta P, Rudelius M, Nikolova V, Keller U, Nilsson JA. Clin Cancer Res. 2011; 17(22):7067-79. 
    
10. 
    Höglund A, Nilsson LM, Forshell LP, Maclean KH, Nilsson JA. Blood. 2009; 113(18):4281-8.
     
11. 
    Nilsson JA, Keller UB, Baudino TA, Yang C, Norton S, Old JA, Nilsson LM, Neale G, Kramer DL, Porter CW, Cleveland JL. Cancer cell. 2005; 7(5):433-44.